Trastuzumab resistance in patients with HER2-positive advanced breast cancer: results from the SONABRE Registry

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

(2021) Larissa A. Korde et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

(2021) Alison E. Smith et al.   Nature Communications

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

(2020) Sandra M Swain et al.   LANCET ONCOLOGY

Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer

(2020) Yada Kanjanapan et al.   BREAST CANCER RESEARCH AND TREATMENT

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2019) F Cardoso et al.   ANNALS OF ONCOLOGY

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

NCCN Guidelines Updates: Breast Cancer

(2018) Sharon H. Giordano et al.   Journal of the National Comprehensive Cancer Network

First‐Line Palliative HER2‐Targeted Therapy in HER2‐Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab‐Based Therapy

(2017) Hánah N. Rier et al.   ONCOLOGIST

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study

(2015) M. Lambertini et al.   ONCOLOGIST

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer

(2014) Rashmi K. Murthy et al.   CANCER

Effectiveness of Trastuzumab in First-Line HER2+ Metastatic Breast Cancer After Failure in Adjuvant Setting: A Controlled Cohort Study

(2014) E. Negri et al.   ONCOLOGIST

Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study

(2013) Ines Vaz-Luis et al.   Clinical Breast Cancer

Pertuzumab: new hope for patients with HER2-positive breast cancer

(2012) M. Capelan et al.   ANNALS OF ONCOLOGY

Resistance to Trastuzumab in Breast Cancer

(2009) P. R. Pohlmann et al.   CLINICAL CANCER RESEARCH